Literature DB >> 29901688

HITTING the Diagnosis: Testing for Heparin-Induced Thrombocytopenia in Cancer Patients.

Maly Fenelus1, Ellinor I B Peerschke1.   

Abstract

OBJECTIVES: To evaluate the use of a pretest probability score (4Ts score) in cancer patients to guide ordering of laboratory screening tests for heparin-induced thrombocytopenia (HIT).
METHODS: A retrospective chart review was conducted for patients (n = 140) in whom laboratory testing for HIT was requested. 4Ts scores were calculated and correlated with heparin-endogenous platelet factor 4 antibody enzyme-linked immunosorbent assay (ELISA) test results.
RESULTS: All patients with a high pretest probability of HIT (4Ts score = 6-7) had positive ELISA results, compared to 26.1% of patients with intermediate (4Ts score = 4-5) and 4.3% of patients with low (4Ts score ≤3) pretest probability. No patients with 4Ts scores of 2 or less had positive ELISA results.
CONCLUSIONS: HIT can be ruled out in cancer patients (negative predictive value and sensitivity = 100%) with low pretest probability, defined by 4Ts scores of 2 or less, significantly reducing the need for laboratory testing in this patient population.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29901688      PMCID: PMC6049042          DOI: 10.1093/ajcp/aqy040

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  18 in total

Review 1.  Heparin-induced thrombocytopenia: pathogenesis and management.

Authors:  Theodore E Warkentin
Journal:  Br J Haematol       Date:  2003-05       Impact factor: 6.998

2.  Interleukin-1 in lipopolysaccharide induced chorioamnionitis in the fetal sheep.

Authors:  Clare A Berry; Ilias Nitsos; Noah H Hillman; J Jane Pillow; Graeme R Polglase; Boris W Kramer; Matthew W Kemp; John P Newnham; Alan H Jobe; Suhas G Kallapur
Journal:  Reprod Sci       Date:  2011-04-14       Impact factor: 3.060

Review 3.  Heparin-Induced Thrombocytopenia: A Comprehensive Clinical Review.

Authors:  Benjamin S Salter; Menachem M Weiner; Muoi A Trinh; Joshua Heller; Adam S Evans; David H Adams; Gregory W Fischer
Journal:  J Am Coll Cardiol       Date:  2016-05-31       Impact factor: 24.094

Review 4.  Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis.

Authors:  Adam Cuker; Phyllis A Gimotty; Mark A Crowther; Theodore E Warkentin
Journal:  Blood       Date:  2012-09-18       Impact factor: 22.113

5.  Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass.

Authors:  A Lillo-Le Louët; P Boutouyrie; M Alhenc-Gelas; C Le Beller; I Gautier; M Aiach; D Lasne
Journal:  J Thromb Haemost       Date:  2004-11       Impact factor: 5.824

Review 6.  The platelet serotonin-release assay.

Authors:  Theodore E Warkentin; Donald M Arnold; Ishac Nazi; John G Kelton
Journal:  Am J Hematol       Date:  2015-05-03       Impact factor: 10.047

7.  Cancer, thrombosis and heparin-induced thrombocytopenia.

Authors:  Paolo Prandoni; Anna Falanga; Andrea Piccioli
Journal:  Thromb Res       Date:  2007       Impact factor: 3.944

8.  Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.

Authors:  G P Visentin; S E Ford; J P Scott; R H Aster
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

9.  A high-value cost conscious approach to minimize heparin induced thrombocytopenia antibody (HITAb) testing using the 4T score.

Authors:  Mohanad Hasan; Pannaga Malalur; Manas Agastya; Ali O Malik; Yaser Dawod; Mohammad Jaradat; Ji-Won Yoo; Ranjit Makar
Journal:  J Thromb Thrombolysis       Date:  2016-10       Impact factor: 2.300

10.  Clinical and laboratory characteristics associated with a high optical density anti-platelet factor 4 ELISA test.

Authors:  Benjamin Y Lu; David Kudlowitz; Lawrence B Gardner
Journal:  J Blood Med       Date:  2015-11-19
View more
  1 in total

1.  The Clinical Efficacy and Economic Benefits of Recombinant Human Thrombopoietin for the Treatment of Chemotherapy or Chemoradiotherapy-Induced Thrombocytopenia.

Authors:  Wenxian Wang; Xiaodong Gu; Lan Shao; Zhiyong Shi; Guangyuan Lou; Zhengbo Song; Yiping Zhang
Journal:  Contrast Media Mol Imaging       Date:  2022-07-14       Impact factor: 3.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.